Big Things In Store For Coeptis

Coeptis Therapeutics ($COEP@US) announced on Thursday morning, August 19, that they had exercised their option to acquire ownership in two technology assets that target CD38 cancers from VyGen-Bio Incorporated, a majority subsidiary of Vycellix. According to the press release, these assets will be co-developed by Coeptis and VyGen-Bio. The transaction follows Coeptis’s initial entry into two separate exclusive option agreements with VyGen as announced on May 18. According to a quote from Dave Mehalick, CEO of Coeptis Therapeutics, “Securing the ownership in the co-development assets for CD38 GEAR NK and CD38 Diagnostics from VyGen is a critical step in the growth of Coeptis Therapeutics, and in the development of these potentially groundbreaking technologies targeting CD38 related cancers.”